Evidence map›Paper›PMID 37795970›Full record

ArticleBiomolecules & biomedicine2024

Early machine learning prediction of hospitalized patients at low risk of respiratory deterioration or mortality in community-acquired pneumonia: Derivation and validation of a multivariable model.

Yewande E Odeyemi, Amos Lal, Erin F Barreto, Allison M LeMahieu, Hemang Yadav, Ognjen Gajic, Phillip Schulte

Open access · diamondAbstract read
In one paragraph

Article in Biomolecules & biomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yewande E OdeyemiDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, United States.
Amos LalDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, United States.
Erin F BarretoDepartment of Pharmacy, Mayo Clinic, Rochester, Minnesota, United States.
Allison M LeMahieuDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, United States.
Hemang YadavDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, United States.
Ognjen GajicDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, United States.
Phillip SchulteDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, United States.
Mayo Clinic · US

Funding

Beta-lactam individualization for critically ill patientsK23AI143882 · NIAID · MAYO CLINIC ROCHESTER · PI BARRETO, ERIN FRAZEE · 2020 to 2024
$986k
Predicting and Preventing Acute Respiratory Distress Syndrome after Hematopoietic Stem Cell TransplantationK23HL151671 · NHLBI · MAYO CLINIC ROCHESTER · PI YADAV, HEMANG · 2021 to 2025
$813k
Individualizing Steroid Use in Pneumonia (Supplement)K23HL168212 · NHLBI · MAYO CLINIC ROCHESTER · PI Yewande Odeyemi · 2023 to 2026
$751k
NHLBI NIH HHS K23 HL151671NHLBI NIH HHS K23 HL168212NIAID NIH HHS K23 AI143882
6 · The paper itself

Abstract

Current prognostic tools for pneumonia predominantly focus on mortality, often neglecting other crucial outcomes such as the need for advanced respiratory support. The objective of this study was to develop and validate a tool that predicts the early risk of non-occurrence of respiratory deterioration or mortality. We conducted a single-center, retrospective cohort study involving hospitalized adult patients with community-acquired pneumonia (CAP) and acute hypoxic respiratory failure from January 2009 to December 2019 (n = 4379). We employed the gradient boosting machine (GBM) learning to create a model that estimates the likelihood of patients requiring advanced respiratory support (high flow nasal cannula [HFNC], non-invasive mechanical ventilation [NIMV], and invasive mechanical ventilation [IMV]) or facing mortality during hospitalization. This model utilized readily available data including demographic, physiologic, and laboratory data, sourced from electronic health records and obtained within the first six hours of admission. Out of the cohort, 890 patients (25.2%) either required advanced respiratory support or died during their hospital stay. Our predictive model displayed superior discrimination and higher sensitivity (cross-validation C-statistic = 0.71; specificity = 0.56; sensitivity = 0.72) compared to the pneumonia severity index (PSI) (C-statistic = 0.65; specificity = 0.91; sensitivity = 0.24; P value < 0.001), while maintaining a negative predictive value (NPV) of approximately 0.85. These data demonstrate that our machine learning model predicted the non-occurrence of respiratory deterioration or mortality among hospitalized CAP patients more accurately than the PSI. The enhanced sensitivity of this model holds potential for reliably excluding low-risk patients from pneumonia clinical trials.

Indexed as

Community-Acquired InfectionsPneumoniaAdultHospitalizationHumansMachine LearningRetrospective Studies

Identifiers

PMID37795970
PMCPMC10950343
OpenAlexW4387328670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.